Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 2/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.99 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.99 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.99 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.99 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.55 |
| ▸ | IL6 | P05231 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24677703 | 0.99 | CYP2E1 (1.00) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL15312497 | 0.99 | CYP2E1 (1.00) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL24677813 | 0.99 | CYP2E1 (1.00) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL823237 | 0.96 | CYP2E1 (0.93) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL29795315 | 0.96 | CYP2E1 (0.93) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL43957 | 0.96 | CYP2E1 (0.93) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL43956 | 0.96 | CYP2E1 (0.93) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL24677704 | 0.96 | CYP2E1 (0.93) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL823185 | 0.93 | CYP2E1 (0.89) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 | |
| SCHEMBL10086290 | 0.90 | CYP2E1 (0.82) | CYP2E1CYP3A4CYP2C9CYP3A5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| EP-2903987-A1 | PHOSPHOLIPID DRUG ANALOGS | Telormedix SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9050319-B2 | Phospholipid drug analogs | TELORMEDIX, SA (CH) | 2015-06-09 | — | — | US | disclosed |
| WO-2014053222-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2014-04-10 | — | — | WO | disclosed |
| US-20130273144-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273144-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | CYP2E1 1769/4885CYP3A4 266/4885CYP2C9 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.